Inhibikase Therapeutics Announces Closing of Initial Public Offering
News provided by
Share this article
Share this article
ATLANTA, Dec. 28, 2020 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase ), a clinical-stage pharmaceutical company developing therapeutics for Parkinson s disease and related disorders that arise inside and outside of the brain, announced today the closing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibikase, were $18 million. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of Inhibikase s common stock at the initial public offering price, less underwriting discounts and commissions.
IPO Alert: Inhibikase Therapeutics (IKT)
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Inhibikase Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 23), under the ticker symbol IKT.
Atlanta, Georgia-based Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics kinase inhibitors for Parkinson s disease and related disorders.
The company has offered to sell 1.8 million shares of its common stock at a price of $10 each. The underwriters have an option for a period of 45 days to purchase up to an additional 270 thousand shares.
The offering, which is scheduled to close on December 28, is expected to fetch gross proceeds of about $18 million for the company.
Share this article
Share this article
ATLANTA, Dec. 22, 2020 /PRNewswire/ Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson s disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per share, for gross proceeds of $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibikase. All of the shares are being offered by Inhibikase. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.